Huntington disease (HD) is caused by an expansion of a Cytosine-Adenosine-Guanosine (CAG) repeat in the *HTT* gene.^[@R1]^ The expansion is driven by paternal transmissions, where the repeat instability correlates with repeat length.^[@R2][@R3][@R5]^ The prevalence of HD varies markedly between populations. The disease is most common among white populations, whereas the prevalence is only a 10th or less in Asian populations.^[@R6]^ Among whites, the Finns and Icelanders have low prevalence, whereas the prevalence rates in other Scandinavian countries are similar to those in other whites.^[@R7],[@R8]^

Shortly after the identification of the *HTT* gene, it was established that the risk of CAG expansion is associated with certain chromosome 4 haplotypes.^[@R9]^ Indeed, differences in the frequency of HD between populations correlate with differences in the frequency of *HTT* haplogroups defined by single-nucleotide polymorphisms (SNPs). Haplogroup A is the most frequent haplogroup in white patients with HD,^[@R10]^ while haplogroup C is the most common one in white general populations. On the other hand, East Asian populations lack haplotypes A1 and A2 and HD cases harbor haplogroup C.^[@R11]^ *HTT* haplogroups have been suggested to differ in the rate of new mutations,^[@R11]^ implying differences in the intergenerational stability of the CAG repeats.

We have previously estimated that the frequency of haplogroup A is lower in the Finnish general population than that in most European populations.^[@R12]^ Here we report the frequencies of *HTT* haplogroups in Finnish patients with HD and in the general population and assess intergenerational stability of CAG repeat expansion across *HTT* haplogroups.

Methods {#s1}
=======

Patients and controls {#s1-1}
---------------------

A previously reported national cohort of patients with HD^[@R12]^ was used to identify families with mutant HTT (*mHTT*). Archival deoxyribonucleic acid (DNA) samples (N = 225) remaining from diagnostic or predictive *HTT* analyses were obtained from the 2 national laboratories that perform HD diagnostics. Family relationships were determined using data from the Population Register Centre, a governmental authority keeping records of citizens, the archives of Family Federation of Finland, a nongovernmental nonprofit welfare organization that has provided genetic counselling to Finnish families with HD, and hospital records. Phasing of CAG repeat and *HTT* haplotype was conducted using data from parent-offspring pairs and other *mHTT* carriers in the family. As controls, we had 292 healthy Finnish blood donors with a mean age of 40.5 years and range 19--64 years.^[@R13]^

The study has been approved by the ethics committee of Hospital District of Southwestern Finland (Dnro ETMK 19/180/2010) and received the national study permits from the National Institute for Health and Welfare (THL, Dnro THL/1456/5.05.00/2010) and the National Supervisory Authority for Welfare and Health, Valvira (Dnro 1195/06.01.03.01/2012). The study involved no contact with patients. Hence, no informed consent was stipulated.

Molecular methods {#s1-2}
-----------------

*HTT* haplogroups A, B, and C were defined using 2 intragenic SNPs, rs762855 and rs4690073, and haplotype A variants were further defined using 4 additional intragenic SNPs, rs2857936, rs363096, rs2276881, and rs362307.^[@R10]^ The SNPs were determined with restriction fragment analysis (FastDigest; Thermo Fisher Scientific, Waltham, MA), allele-specific amplification using locked nucleic acid (LNA) primers (Exiqon, Vedbaek, Denmark), or by sequencing (ABI3500xL Genetic Analyzer, Applied Biosystems, Foster City, CA) as appropriate (table e-1, [links.lww.com/NXG/A153](http://links.lww.com/NXG/A153)). The PCRs were performed using Phire Hot Start II DNA Polymerase (Thermo Fisher Scientific) according to the standard procedures. The LNA amplifications were conducted in duplicates or confirmed by sequencing. Additional SNPs (table e-1, [links.lww.com/NXG/A153](http://links.lww.com/NXG/A153)) were analyzed in samples, where haplogroup A variant remained undetermined.^[@R10],[@R14]^ Haplotypes were manually annotated and then phased to CAG repeat length by familial relationship or by homozygosity of haplotype.

Statistical analysis {#s1-3}
--------------------

Exact test of population differentiation as implemented in Arlequin 3.5^[@R15]^ was used to compare frequencies of haplogroups between cases and controls. Chi-square test or *t* test was used to compare 2 groups as appropriate.

Data availability statement {#s1-4}
---------------------------

Access to data was regulated by the Finnish law, THL, and Valvira. Permission to conduct this study prohibits disclosing data to third parties without explicit permission from THL and Valvira. Those fulfilling the requirements for viewing confidential data as required by the Finnish law and who receive the permission from THL and Valvira are able to access the data.

Results {#s2}
=======

Frequencies {#s2-1}
-----------

The allele frequencies of *HTT* haplotypes in the Finnish population differed from those in 411 non-Finnish European subjects^[@R11]^ (*p* \< 0.00001, exact test of population differentiation). The frequency of haplogroup A was lower (*p* = 0.0003, χ^2^ test) than that in Europeans, and haplogroup C was higher (*p* = 0.046, χ^2^ test), but there was no difference in the proportion of haplotypes A1 and A2 out of all haplogroup A alleles.

The allele frequencies of *HTT* haplotypes among Finnish patients with HD and unsymptomatic *mHTT* carriers differed from those in the controls (*p* \< 0.00001, exact test of population differentiation). Haplogroup A alleles were significantly more common in patients than in controls, while haplogroup B and C alleles were more common in population controls ([table 1](#T1){ref-type="table"}). Frequencies of haplotypes A1--A5 differed between controls and patients with HD (*p* \< 0.00001, exact test of population differentiation). Among patients with HD (including unsymptomatic *mHTT* carriers), haplotypes A1 and A2 were more frequent and haplotypes A4 and A5 less frequent than among the controls (*p* = 0.003, exact test of population differentiation).

###### 

Frequencies of *HTT* haplotypes in Finnish patients with HD and controls
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Transmissions {#s2-2}
-------------

We were able to analyze the change in the size of *mHTT* CAG repeat in 65 transmissions ([table 2](#T2){ref-type="table"}). The mean size of the change was +1.38 CAG units in paternal transmissions being larger than that in maternal transmissions (−0.17 CAG units) (*p* = 0.008, *t* test). *mHTT* haplotype SNPs and CAG repeat could be phased in 50 transmissions (haplogroup A, 38; haplogroup C, 10; other haplogroup, 2; [figure 1](#F1){ref-type="fig"}). *mHTT* CAG repeats in haplogroup A (42.6 CAG units) were shorter than those in haplogroup C (48.4 CAG units). In haplogroup C, the *mHTT* CAG repeats decreased in paternal as well as maternal transmissions (*p* = 0.74 for gender difference), whereas the mean increase of the repeats in haplogroup A was considerable in paternal transmissions (3.18 CAG units) but meager in maternal transmissions (0.11 CAG units) (*p* = 0.008 for difference) ([figure 2](#F2){ref-type="fig"}). The gender difference in *mHTT* CAG change was significant in haplotype A1 inheritances (*p* = 0.022), but not in haplotype A2 or A3 inheritance.

###### 
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![Proportions of changes in *mHTT* CAG repeat tracts in transmission events in 48 Finnish families with Huntington disease\
Two families belonging to haplogroups other than A or C are not included. (A) Changes in haplogroups A and C. (B) Changes in haplogroup A haplotypes.](NG2019010264f1){#F1}

![Mean change in *mHTT* CAG repeat length in maternal and paternal transmission events in 48 Finnish families with Huntington disease\
Two families belonging to haplogroups other than A or C are not included. Changes are shown for haplogroup A haplotypes and for haplogroup C.](NG2019010264f2){#F2}

Discussion {#s3}
==========

We found remarkable differences in intergenerational CAG repeat dynamics that depended on *HTT* haplotype and parent gender. *HTT* haplotype A1 was not only associated with HD, but also showed a predilection to CAG repeat expansion in paternal transmissions. Repeat tracts on haplotypes A2 and A3 showed propensity to expand, whereas those on haplogroup C showed a preference for contraction irrespective of parental gender.

Previous studies have shown that paternal transmission drives intergenerational CAG expansion in *HTT*.^[@R2][@R3][@R5]^ We identified 65 Finnish parent-child pairs, where paternal transmission was associated with repeat expansion (+1.38 CAG units), whereas maternal transmission mainly resulted in repeat contraction (−0.17 CAG units). Strikingly similar figures have been obtained in 337 parent-offspring transmissions in Dutch patients, where paternal transmission was associated with CAG repeat expansion (+1.76 CAG units) and maternal transmissions resulted in contraction (−0.07 CAG units).^[@R3]^ These findings suggest that intergenerational stability of *mHTT* in Finnish HD families does not differ from that in other white populations. Interestingly, the intergenerational stability of the CAG repeat differed between *mHTT* haplotypes. On average, repeat tracts on haplotype A1 gained length in paternal transmissions, while maternally inherited tracts decreased in length. Haplotype A1 seems to be a major contributor to paternal anticipation in HD, as 48% of all the pathogenic expansions were on haplotype A1.

We found that repeat tracts on haplogroup C were larger than those on haplogroup A and that repeat tracts on haplogroup C showed a tendency to contract. Indeed, the ratio between the number of contraction events and the number of expansion events was 2.0 in haplogroup C transmissions, while the corresponding ratio was 0.4 in haplogroup A transmissions ([figure 1A](#F1){ref-type="fig"}). The skew toward contraction suggests that *HTT* haplogroup C harbors DNA sequence elements that favor contraction in previously elongated repeat tracts. These findings should be interpreted with caution, however, as *HTT* haplotype and CAG repeat could be phased in only 10 haplogroup C samples. The haplogroup C samples showed a tendency for contraction in both paternal and maternal transmissions, which resembles the findings in some Cretan HD families.^[@R16]^ The repeat tracts are stable or contract in transmission in these families and, clinically, the families do not show anticipation.

Remarkable ethnic differences in the prevalence of HD have suggested a genetic contribution. The frequency is highest among European populations and a recent systematic review compiled 14 studies and found that the median prevalence is 5.7/100,000 (range 0.96--11.8).^[@R6]^ The lowest prevalence rates included in the review were 0.96/100,000 in Iceland^[@R17]^ and 2.14/100,000 in Finland.^[@R12]^ In the European population, CAG expansions occur predominantly on haplotypes A1 and A2, which are present in 20% of the individuals with \<27 CAG repeats.^[@R10],[@R11]^ We found that haplogroup frequencies in the Finnish general population differ from those among non-Finnish Europeans. In particular, haplogroup A was low, and thus the low frequency of the susceptibility haplogroups partly explains the low HD prevalence in the Finnish population. Similar to other white populations, the majority of HD cases in Finland harbored haplotype A1 or A2 and the 2 haplotypes constituted similar proportions of haplogroup A chromosomes.

In addition to *HTT* haplotype, other possible contributors to variation in prevalence rates include differences in the rate of new mutations and founder effect. A recent analysis has suggested that a higher frequency of haplotype A1 in the general population yield a higher rate of new HD mutations.^[@R18]^ Hence, the relatively low rate of new mutations would be the mechanism producing low prevalence of HD in the Finnish population by virtue of the low proportion of *HTT* haplotypes A1 and A2. In Finland, the haplotype distribution may be because of small founder population and geographic, cultural, and linguistic isolation have shaped the gene pool of the Finnish population.^[@R19]^ These events have yielded Finnish disease heritage, where certain Mendelian diseases are enriched in the population, while some others are lacking or occur at a low prevalence, such as HD.^[@R12]^ The population genomics also shows some ancient features that are undetectable in most other regions of Europe.^[@R20]^

Taking into account the low frequency of HD in Finland, our sample set of 225 is rather comprehensive. The archival nature of the samples posed some limitations, as lack of samples precluded phasing in many families. However, homozygosity of the *HTT* haplotype or results from 79 out of the 225 samples enabled us to phase *HTT* haplotype and CAG repeat in 50 transmissions.

Here we found that the intergenerational stability of the CAG repeat differed between *mHTT* haplotypes. Repeat tracts on haplotype A1 gained length only in paternal transmissions, while paternally as well as maternally inherited tracts decreased in length on haplogroup C. In addition, we showed that the frequency of the HD-associated *HTT* haplogroup A was lower in the Finnish population than that in the non-Finnish European population and that the frequency of haplogroup A was higher in patients with HD than that in the population. These findings at least partly explain the low prevalence of HD in Finland.
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